Watch Matthew McCurdy, M.D., radiation oncologist at Austin CyberKnife, discuss prostate cancer, how it is treated with the CyberKnife® Robotic Radiosurgery System and CyberKnife treatment benefits for patients, on KXAN’s Studio 512.

Learn More

Watch Douglas J. Rivera, M.D. radiation oncologist and Medical Director at Austin CyberKnife and Subir Chhikara, M.D., urologist at Austin Urological Associates discuss the risk factors, signs, symptoms, and stats associated with prostate cancer, prostate cancer screenings, and how prostate cancer is treated with the CyberKnife® Robotic Radiosurgery System on KXAN’s Studio 512.

Learn More

Last week, the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) released collaborative clinical guidelines for managing localized prostate cancer which offers a framework for shared decision-making between physicians and patients.  Through this collaboration, the committee provided guidance on active surveillance and on which treatments […]

Learn More

  Watch general surgeon, Dr. Louis Heuser, talk about why he chose CyberKnife for the treatment of his prostate cancer. Dr. Heuser was very happy with the quick treatments and the fact that he was able to stay close to home and continue to work and see his patients. It’s Your Prostate, Your Cancer, Your […]

Learn More

Learn More

A recent research paper in Oncotarget, a weekly peer-reviewed open access medical journal covering research on all aspects of oncology, reported that researchers from UR Medicine’s Wilmot Cancer Institute and Roswell Park Cancer Institute have discovered a possible new tool for predicting whether prostate cancer will reoccur following surgery based on the expression patterns of […]

Learn More

Learn More

According to research presented at the recent 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), high dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates.    Although prostate tumors generally respond well to radiation […]

Learn More

A recent study found that mid-life prostate-specific antigen (PSA) levels predict who will be more likely to develop lethal prostate cancer.  Investigators from Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health found that measuring PSA levels in younger men (between the ages of 40 and 59) could accurately predict future […]

Learn More